TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05603559
Drug: 1.1 GBq (30 mCi) of 177Lu-P17-088
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients were intravenous injected with single dose 1.1 GBq (30 mCi) of 177Lu-P17-088 then monitored at 1.5 hours, 4 hours, 24 hours, 48 hours, 72 hours, 120 hours and 168 hours post-injection.
Study: NCT05109663
Drug: SKLB1028
Approvals — FDA: no, EMA: no, PMDA: no
Description: SKLB1028, capsule, oral
Study: NCT00000644
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05512039
Drug: Botox 50 Unit Injection
Normalized name: onabotulinumtoxinA 200 UNT [Botox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat treatment up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
Study: NCT05454462
Drug: IMP Application KM-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: KM-001 will be supplied in glass jars (30 ml) and will be provided to patients with spatulas and polyethylene gloves on all the clinical visits. the patient will use IMP twice a day for 28 days.
Study: NCT06389344
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same amount of normal saline will be infused intravenously at a constant speed within 30 min after tracheal intubation/pneumatectomy fixation.
Study: NCT05512039
Drug: Botox 100 Unit Injection
Normalized name: onabotulinumtoxinA 100 UNT [Botox]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be randomized to either receive a standard dose (100 units) or reduced dose (50 units) of onabotulinumtoxinA. If a participant has decreased symptom relief they may receive repeat injection up to twice during the 12 month follow-up period, with minimum 4 month intervals between treatments.
Study: NCT05370976
Drug: Cytotect®CP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytotect®CP in two phases:~Induction phase: 1 ml/kg/week for 4 weeks Maintenance phase: 1 ml/kg/2 weeks for 12 weeks or corticosteroid dose \< 0.5 mg/kg, according to which condition occurs first.~Patients developing CMV infection under Cytotect®CP must be given standard anti-CMV treatment (Gancyclovir or Foscarnet) according to their center procedure. Cytotect®CP will be maintained
Study: NCT06271681
Drug: 15-valent pneumococcal conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDA approved pneumococcal vaccines 15 valent conjugate vaccine administered at enrollment
Study: NCT05293600
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule 30 min before bedtime
Study: NCT05733741
Drug: Preservative-free Benoxinate hydrochloride 0.4% (Benoxidia unit-dose vials [UD], Orchidia pharmaceutical Ind., Egypt)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each patient, one eye was treated with preservative-free Benoxinate hydrochloride 0.4%.~The prescribed regimen comprises of the instillation of one drop immediately, 2, 4, 6 and 8 hours after the end of surgery.~Every patient was given 5 UD vials only of preservative-free Benoxinate hydrochloride 0.4% at each follow up visit for the next postoperative day usage administered 5 times daily (every 3 hours while awake) for the first 3 postoperative days giving clear instructions to immediately discard the vial after single use.
Study: NCT05396339
Drug: IAE0972
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAE0972 is an investigational product
Study: NCT05446883
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT05085275
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will be instructed to take study drug (ferric citrate or placebo) at a fixed dose of 2 tablets per meal or snacks, up to three times per day. The maximum dose is 6 tablets per day. No additional tablets (beyond a total of 6 per day) should be taken. Tablets should not be crushed or chewed.
Study: NCT04941183
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05232279
Drug: Testofen 300mg
Normalized name: Ketofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testofen in capsule form - To be taken as a 300mg dosage (2 capsules) once daily for 12 weeks.
Study: NCT05232279
Drug: Testofen 600mg
Normalized name: Ketofen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testofen in capsule form - To be taken as a 600mg dosage (2 capsules) once daily for 12 weeks.
Study: NCT05232279
Drug: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo will consist of maltodextrin and will appear identical to the Testofen capsules. The placebo will be administered as per the active treatment - 2 capsules once daily for 12 weeks.
Study: NCT05798546
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide 500 mg/m2/day iv on day-5 for one day.
Study: NCT04770467
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given by intravenous administration
Study: NCT06443762
Drug: [68Ga] MDM2/MDMX Peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Utilizing a peptide with high affinity to MDM2/MDMX as the targeting moiety for radiopharmaceuticals, this study explores the diagnostic efficacy of \[68Ga\] MDM2/MDMX Peptide in patients with malignant tumors exhibiting high MDM2/MDMX expression. This approach not only provides a basis for the early diagnosis of malignant tumors but also facilitates the formulation of effective precision therapy strategies tailored to the tumor's MDM2/MDMX expression profile, particularly for patients with recurrent and metastatic disease.~\[68Ga\] MDM2/MDMX Peptide, a novel MDM2/MDMX-targeted molecular probe labeled with 68Ga, utilizes DOTA as a bifunctional chelator for complexing with 68Ga3+. The labeling process is straightforward, allowing for direct use without purification, and demonstrates high in vivo stability.
Study: NCT05825066
Drug: mFOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention will be administered on an outpatient basis. The patients on this study will begin treatment with GA for one month and then transition to mFFX for one month.~The patient will come off of the sequence study intervention if the imaging after the 2nd month shows unequivocal progression. After four months of sequential neoadjuvant therapy the patient will come off study and can proceed to surgery, radiation, or extended course of chemotherapy as determined by the multidisciplinary tumor board consensus or the treating physician.
Study: NCT04806061
Drug: standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard care
Study: NCT05410925
Drug: Recombinant staphylokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Study: NCT05410925
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of placebo is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Study: NCT06284460
Drug: ASTX029
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06284460
Drug: ASTX727
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given by PO
Study: NCT06096090
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration
Study: NCT05507567
Drug: Neumifil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid for intranasal spray administration
Study: NCT05507567
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid for intranasal spray administration
Study: NCT05349968
Drug: Lipovirtide for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple dosing of Lipovirtide
Study: NCT05778864
Drug: LY3473329
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally.
Study: NCT05780801
Drug: Allogeneic Microbiota in Glycerol (10%) (AMG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with positive MDRO cultures will receive MT instilled via a functional feeding tube when in place or rectal enema (when a functional feeding tube is not present) with the rate adjusted to the recipient's clinical status and infusion tolerance.
Study: NCT05568160
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The infusion is started at 5 ml h-1, increased in increments of 1 ml h-1 every 5 minutes to a maximum target rate of 30 ml h-1
Study: NCT02388477
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: antibiotic used to treat infection
Study: NCT05521191
Drug: RGLS8429
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection
Study: NCT05521191
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for subcutaneous injection
Study: NCT04657133
Drug: Standard medication therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard medication therapy will be performed according to the national and international guidelines.
Study: NCT05524519
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Health education: Properly explain the causes and precautions of the patient and instruct the patient to rest regularly. In addition, care should be enhanced to avoid accidents.~2. The basic therapeutic drug is the use of one or more antidepressants, such as oral 5-hydroxytryptamine reuptake inhibitors, dual inhibitors of pentraxin and norepinephrine reuptake, noradrenergic and specific pentraxinergic antidepressants, pentraxin receptor balance antagonists, tricyclic antidepressants, etc. If there is significant sleep disturbance, benzodiazepines may be added temporarily. Dosing and dosage will be adjusted by a specialist.
Study: NCT05561816
Drug: Hydroxymethylquinoxalindioxyde
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dioxidin®, 0.025% solution for local and external use (Valenta Farm, Russia).
Study: NCT05745337
Drug: As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)
Normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will stop their daily beta-blocker and take as-needed rate control (beta-blocker or calcium channel blocker) guided by their implantable cardiac monitor
Study: NCT06097533
Drug: Cannabisextrakt Avextra 10/10 Lösung
Approvals — FDA: no, EMA: no, PMDA: no
Description: medical cannabinoids
Study: NCT06247345
Drug: ADEL-Y01 - healty participants
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: In our Part 1 clinical trial, we plan to enroll up to 40 healthy participants, aged 18 to 65, to test the safety and tolerability of ADEL-Y01. The study is divided into 5 cohorts, each with 8 participants, where 6 receive a single dose of ADEL-Y01. Screening is done 28 days prior, followed by randomization and dosing. Participants undergo initial assessments until Day 4 and additional safety and PK evaluations over 12 weeks. Starting at 2.5 mg/kg, the ADEL-Y01 dose may increase up to 100 mg/kg based on Safety Review Committee assessments, ensuring a detailed evaluation of the drug's safety.
Study: NCT06247345
Drug: Placebo - Healthy Participants
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 1 of our trial, we will enroll 2 placebo participants per cohort in up to 5 cohorts, undergoing the same protocol as those receiving ADEL-Y01 but with a placebo. They'll be part of the study from Day -1 to Day 4 for initial assessments and continue for 12 weeks for further safety and PK evaluations. This inclusion of placebo groups ensures a blinded study design for unbiased comparison of ADEL-Y01's safety and efficacy.
Study: NCT06247345
Drug: ADEL-Y01 - MCI/AD
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 2 of our trial, we assess ADEL-Y01 in 33 participants aged 50 to 80 with MCI or mild AD, administering multiple IV doses every 2 weeks for 12 weeks. Each of the 3 cohorts will have 8 participants receiving ADEL-Y01, totaling 6 doses. After initial screening and consent, participants are randomized to start treatment on Day 1, with a follow-up in the clinical research unit for safety assessments. Additional safety and PK assessments occur bi-weekly up to 22 weeks, based on the start from the last dose on Day 71.~Doses are set at 7.5, 20, and 50 mg/kg, adjusted based on Part 1 results and SRC safety reviews after at least 3 doses over 6 weeks. This phase focuses on understanding ADEL-Y01's safety and efficacy in AD patients through a cautious dosing strategy.
Study: NCT06247345
Drug: Placebo - MCI/AD
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 2 of our clinical trial focusing on patients with MCI or mild AD, alongside the active treatment groups, we plan to include placebo groups within the 3 cohorts. Out of the 33 participants aged 50 to 80, 3 in each cohort, totaling 9 participants, will receive a placebo instead of the active drug, ADEL-Y01, administered every 2 weeks for 12 weeks. These placebo participants undergo the same screening, consent, and randomization procedures as those receiving the active drug. They are administered the placebo following the same schedule as the active groups, ensuring a controlled and blinded study environment to accurately assess ADEL-Y01's effects without bias.~Placebo participants are crucial for comparing the active drug's impact on safety, tolerability, and effectiveness against a non-therapeutic intervention, maintaining the study's integrity and providing a benchmark for evaluating ADEL-Y01's true pharmacological effects on MCI or mild AD conditions.
Study: NCT05170958
Drug: LBL-024 for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBL-024 was given every three weeks for treatment
Study: NCT05646784
Drug: Cerebiome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evaluate the effect of oral intake of a probiotic agent on plasma inflammatory markers, gut bacterial profile and depressive state in a subgroup of target patients versus a subgroup treated with placebo
Study: NCT05646784
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo effect: Evaluate the effect of oral intake of a placebo, on clinical and plasma inflammatory markers, in a subgroup treated with placebo, in combination with conventional treatment for 12 weeks
Study: NCT06091943
Drug: Histology-Based Chemotherapy Doublet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy Doublet 1: Cisplatin/carboplatin + pemetrexed.~Chemotherapy Doublet 2: Carboplatin + paclitaxel/nab-paclitaxel.~Choice of histology-based induction chemotherapy doublet will be determined by the investigator and will be administered at standard doses intravenously.
Study: NCT04244981
Drug: Fresh Frozen Plasma
Normalized name: Fresh frozen plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: When APTT is prolonged (\> 45 s) measured 20 minutes after CPB or excessive bleeding observed, patients will be given 6～10 mL/kg FFP.
Study: NCT06049095
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses
Study: NCT06474520
Drug: Calculus bovis sativus (CBS)
Normalized name: Mycobacterium bovis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will orally receive 100mg CBS per day from day 1 to day 84.
Study: NCT06014853
Drug: SOL-804-F
Normalized name: F
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects who have been fasting for at least 10 hours prior to administration will take investigational products orally with water on the administration day of each period.
Study: NCT05291546
Drug: REGN9035
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Single dose administered by IV infusion on day 1. Part B: Selected doses administered by IV infusion on day 2 or 22.
Study: NCT05291546
Drug: REGN5381
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part B: Selected doses administered by IV infusion on day 1.
Study: NCT04930861
Drug: Covidir injections
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.
Study: NCT06547333
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05808010
Drug: Weifuchun+Hydrotalcite/L-Glutamine and Sodium Gualenate Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally delivered tablets for 7 months. Take it according to the instructions.
Study: NCT05081167
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT04990063
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy drug
Study: NCT05769855
Drug: HR18034
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR18034 380mg
Study: NCT06221761
Drug: not using antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: no antibiotic application
Study: NCT06221761
Drug: using antibiotic
Normalized name: Antibiotics for systemic use
Approvals — FDA: no, EMA: no, PMDA: no
Description: antibiotic application
Study: NCT05895877
Drug: Goofice®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily before breakfast.
Study: NCT05895877
Drug: Goofice® Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily before breakfast.
Study: NCT05956431
Drug: physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo group received continuous intravenous infusion of physiological saline at the rate of 0.05-0.2 μg/kg/min for 24 hours, while also receiving comprehensive cluster therapy with PCAS.
Study: NCT05725512
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone tablets (20 mg daily for 6 weeks, 10 mg daily for 1 week, 5 mg daily for 1 week) or identical placebo tablets for 8 weeks
Study: NCT05725512
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo identical to prednisolone tablets
Study: NCT05844111
Drug: [14C]-BGB-11417
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of liquid formulation
Study: NCT05292495
Drug: HR17031 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: HR17031 injection; administered subcutaneously.
Study: NCT05577000
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04985201
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 40 mg daily oral tablet taken.
Study: NCT04303000
Drug: Opioid Overdose Education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online audiovisual training focused on recognizing the signs of an opioid overdose and administering naloxone. Participants are provided with information on where they can obtain a naloxone kit.
Study: NCT06318845
Drug: DHP2302R1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg per dose, once daily
Study: NCT06318845
Drug: DHP2302R2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg per dose, once daily
Study: NCT06341114
Drug: BAT8008 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAT8008 for injection is a sterile, preservative-free lyophilized powder packaged in vials, with each vial containing 100 mg,Prior to infusion, reconstitute with 5 milliliters of sterile water for injection. After reconstitution, a clear to slightly opalescent, colorless to pale yellow solution with a final concentration of 20 mg/mL can be obtained.
Study: NCT06341114
Drug: BAT1308 injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: One vial of 4 mL of concentrate contains 100 mg of BAT1308
Study: NCT06537765
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: All women with endometriosis in all groups (A, B, \& C) will receive their medical treatment as prescribed by the gynecologist.
Study: NCT04701606
Drug: Artecom® (pyronaridine-artesunate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \* Participant body weight (Artecom® dose)~* ≥ 65kg (Artecom® 4 tablets: Pyronaridine 720mg/ Artesunate 240mg)~* ≥ 45kg and \< 65kg (Artecom® 3 tablets: Pyronaridine 540mg/ Artesunate 180mg)
Study: NCT04701606
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: \* Participant body weight (Placebo dose)~* ≥ 65kg (Placebo 4 tablets)~* ≥ 45kg and \< 65kg (Placebo 3 tablets)
Study: NCT05626140
Drug: Codeine Phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Codeine Phophate is an opioid with centrally acting pain alleviating mechanisms, shorter half life and metabolized to morphine in he body which is its active metabolite
Study: NCT05626140
Drug: Diclofenac Sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium is a Cox 2 inhibitor non steroidal anti inflammatory drug with a half life of only 1.2 hrs but a longer action of duration due to its property to get distributed to synovial fluids. metabolized to hydroxy diclofenac and excreted via urine and bile both.
Study: NCT00002140
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002140
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT06652412
Drug: Ultrafractionated RT and CGA Guided systemic treatment.
Approvals — FDA: no, EMA: no, PMDA: no
Description: in cohort 1, all patients will receive Ultrafractionated RT (1Fx every 3 or 4weeks) and Sintilimab (q3w). Furthermore, CGA will assess all patients and classify them into Frail, Vulnerabe, or Fit. Frail patients will receive Best Supportive Care (BSC); Vulnerabe patients will receive Fluorouracil/Raltitrexed and BSC; Fit patients will receive Fluorouracil/Raltitrexed, Oxaliplatin/Irinotecan, and BSC.
Study: NCT06652412
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-Fluorouracil or capecitabine
Study: NCT06093308
Drug: Deuremidevir Hydrobromide Tablets
Normalized name: hydrobromic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple administration, oral administration after meals, D1: 0.6g, twice a day; D2-D5: 0.3g, twice a day; D6: 0.3g, administered once in the morning
Study: NCT06481085
Drug: HDM1002 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM1002 tablets, 50 mg once daily, 12 weeks
Study: NCT06481085
Drug: HDM1002 100 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM1002 tablets, 100 mg once daily, 12 weeks
Study: NCT06481085
Drug: HDM1002 200 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM1002 tablets, 200 mg once daily, 12 weeks
Study: NCT06481085
Drug: HDM1002 400 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM1002 tablets, 400 mg once daily, 12 weeks